Samer Ezziddin

Modern Nuclear Medicine / Cancer Targeted Therapy | Focus on Neuroendocrine Tumors - Prostate Cancer - Liver/Bone Mets - Lu177 PSMA/PRRT/SIRT Radioembolisation

[Garry Kasparov @Kasparov63]

Ukraine is paying a high price in blood and terror. They are not the first and will not be the last if Russia isn’t defeated now. This is the lesson I wish the West would finally figure out. The price always goes up. There will be no better chance than now.

[Michael Hofman @DrMHofman]

📣 Just released! Joint @EANM_NucMed @SNM_MI Lu-177 PSMA guidelines. Step forward in improving the standard of care for delivery of radioligand therapy. @ProfKHerrmann
https://t.co/6FVNWo5k2A

[Ricardo Soares @soares_uro]

Metastasis-directed therapy (MDT) in prostate cancer with SABR/SBRT and sLND:
- postpone need for ADT
- improved PFS
- one study with improved OS with SOC + SABR
@jeffkarnesMD @MayoUrology #AUA23

[Samer Ezziddin @Prof_Ezziddin]

Terbium-161 may become an interesting alternative to Lutetium-177, here an example in PSMA-targeted Radioligand Therapy…. #Terbium #Tb161 #RLT #PSMA #prostatecancer

[Samer Ezziddin @Prof_Ezziddin]

https://t.co/4OH6ySrqdu

[Michael Hofman @DrMHofman]

It's a paradigm changing concept, uncomfortable to many: PET/CT images "live" pathology, and may be better than dead tissue biopsies in *some* circumstances.

[Michael Hofman @DrMHofman]

#ProPSMA 54 month follow-up #EAU23 "live" @declangmurphy
✓ PSMA PET/CT N1 prognostic for failure - HR 2.1
✗ CT/BS not prognostic
= PSMA PET/CT findings significant. More and more longer term data supporting it's use.
Presented by @veerukasi Funding @MovemberAUS @PCFA @pros_tic

[Samer Ezziddin @Prof_Ezziddin]

https://t.co/4OH6ySrqdu

[Michael Hofman @DrMHofman]

Saw another patient this week misclassified as progression on DOTATATE PET/CT when the change was likely due to commencement of long-acting octreotide therapy. "Pseudoprogression" under-recognised phenomenon:
https://t.co/kLDWhzUFx1
@globeseek @marklewismd @OncoThor

[Samer Ezziddin @Prof_Ezziddin]

Radioliganden-Therapie: Wie eine neue Behandlung Prostatakrebs schrumpfen lässt https://t.co/1da4VbGUeI via @welt

[PRIMO MEDICO GmbH @PrimoMedico]

🤖🧠 #RobotischeNeurochirurgie: Präzise OPs ohne ermüdende oder zitternde Hände & Arme - Prof. Uwe Spetzger erklärt #Robotik im Spezialisten-#Podcast 🆕🆓🎧 https://t.co/7Am4LR6pGe

🏅 PRIMO MEDICO #Neurochirurgie @KlinikKarlsruhe 💡 https://t.co/LGxDo7Kkci

[Samer Ezziddin @Prof_Ezziddin]

@Biomol_MDPI

[Samer Ezziddin @Prof_Ezziddin]

PSMA-Therapie für die Behandlung des metastasierenden Prostatakarzinoms ... https://t.co/LhZqfa6SGr via @YouTube

[Arun Azad @AzadOncology]

Very excited to announce our latest Lu-PSMA trial @PeterMacCC: Ph I/II LuCAB trial (Lu-PSMA + cabazitaxel) for mCR #ProstateCancer. Target accrual 40 pts. Strong rationale for combining Lu-PSMA with cabazitaxel - radiosensitisation, Rx PSMA-neg disease, use 2 drugs that ⬆️ OS.

[Samer Ezziddin @Prof_Ezziddin]

https://t.co/55jBDMaaqq

[Samer Ezziddin @Prof_Ezziddin]

@CalaisJeremie @baumrp Sharply observed Jeremie! Not many dealing a lot with PSMA imaging have understood the huge potentialem late imaging! For radiation oncologists it is a great opportunity to apply salvage Rx in a more targeted or boosted approach with positive findings..

[Samer Ezziddin @Prof_Ezziddin]

@CalaisJeremie Thanks Jeremie for highlighting!

[Jeremie Calais @CalaisJeremie]

Nice illustration of (very) late PSMA PET imaging at +3 days with Zirconium-89: Digestive activity and late tracer retention in a local recurrence focus of prostate cancer after surgery. By Florian Rosar and Samer Ezziddin @Prof_Ezziddin #PSMA #theranostics #prostatecancer #PETCT

[PRIMO MEDICO GmbH @PrimoMedico]

🆕🎧🆓Neuer #Podcast: PSMA #RadioligandenTherapie, realisierte Traumbehandlung bei #ProstataKrebs, mit Prof. Samer Ezziddin vom Universitätsklinikum des Saarlandes. Jetzt anhören! https://t.co/SGqwDkWYDA
👉PRIMO MEDICO #NuklearMediziner: https://t.co/P58UfjdkZS
#ProstataKarzinom

[EuropeanHospital_D @EuropHospital_D]

#Nuklearmedizin: Mit einer Bestrahlung durch radioaktive Substanzen wie etwa Lutetium-177 können Prostatatumore sowie ihre Metastasen zumindest eine Zeitlang unter Kontrolle gebracht werden. @Saar_Uni @Prof_Ezziddin #Prostatakrebs #Strahlentherapie https://t.co/AG9Jj0vuhW

[Declan Murphy @declangmurphy]

@ReneaTaylor1 @PCF_Science @Ecastromarcos @EUplatinum Plus accompanying editorial emphasizes this nicely @DrMLChua #prostatejc https://t.co/og5j0SStMn